Literature DB >> 1359575

Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa.

C G Charlton1, B Crowell.   

Abstract

The major symptoms of Parkinson's disease (PD) are due to degeneration of the nigrostriatal pathway and depletion of dopamine (DA). Tyrosine hydroxylase (TH), norepinephrine (NE), serotonin (5-HT), and melanin pigments are also decreased and acetylcholinergic activity increased. Biochemically, increased methylation can cause the depletion of DA, NE, 5-HT, and melanin pigments and also an increase of acetylcholine; thus, increased methylation can present a biochemical picture that resembles the biochemical changes that occur in PD. During the therapy of PD with L-dopa, it is well known that L-dopa reacts avidly with S-adenosyl-L-methionine (SAM), the biologic methyl donor, to produce 3-O-methyl-dopa. Correspondingly, L-dopa has been shown to deplete the concentration of SAM, and SAM has been found to induce PD-like motor impairments in rodents; therefore, an excess of SAM-dependent methylation may be associated with Parkinsonism. To further study the effects of methylation, SAM was injected into the lateral ventricle of rats. SAM caused tremors, rigidity, abnormal posture, and dose-related hypokinesia. Doses of 9.38, 50, and 400 nM/rat caused 61.9, 73.4, and 94.8% reduction, respectively, of motor activity. A 200-mg/kg IP dose of L-dopa, given before 50 nM SAM, blocked the SAM-induced hypokinesia. SAM also caused a decrease in TH immunoreactivity, apparent degeneration of TH-containing fibers, loss of neurons, and the accumulation of phagocytic cells in the substantia nigra. These results showed that excess SAM in the brain, probably due to its ability to increase methylation, can induce symptoms that resemble some of the changes that occur in PD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359575     DOI: 10.1016/0091-3057(92)90172-c

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  Amino acid management of Parkinson's disease: a case study.

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Int J Gen Med       Date:  2011-02-28

2.  Parkinson's disease managing reversible neurodegeneration.

Authors:  Marty Hinz; Alvin Stein; Ted Cole; Beth McDougall; Mark Westaway
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-05       Impact factor: 2.570

3.  "Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemic.

Authors:  Kenneth Blum; Edward J Modestino; Marjorie Gondré-Lewis; B William Downs; David Baron; Bruce Steinberg; David Siwicki; John Giordano; Thomas McLaughlin; Jennifer Neary; Mary Hauser; Lyle Fried; Rajendra D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2017-11-17

4.  5-HTP efficacy and contraindications.

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-19       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.